MediWound Ltd. Files 6-K Report

TL;DR

MediWound Ltd. (MDWD) filed a 6-K, confirming foreign private issuer status and 20-F filings.

AI Summary

MediWound Ltd. filed a Form 6-K on August 5, 2024, reporting as a foreign private issuer. The filing indicates the company is subject to the reporting requirements of the Securities Exchange Act of 1934 and will file its annual reports on Form 20-F. The company is located at 42 Hayarkon Street, Yavne, Israel.

Why It Matters

This filing confirms MediWound Ltd.'s status as a foreign private issuer and its adherence to SEC reporting standards, which is crucial for investors tracking the company's regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing confirming the company's reporting status and not indicating any new financial or operational developments.

Key Players & Entities

• MediWound Ltd. (company) — Registrant
• Securities Exchange Act of 1934 (legal_document) — Governing regulation
• Form 20-F (legal_document) — Annual report form
• 42 Hayarkon Street Yavne, 8122745 Israel (location) — Principal executive offices

FAQ

Filing Documents

• zk2431776.htm (6-K) — 11KB
• exhibit_99-1.htm (EX-99) — 22KB
• 0001178913-24-002405.txt ( ) — 34KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-36349 MediWound Ltd. (Translation of registrant's name into English) 42 Hayarkon Street Yavne, 8122745 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __ EXPLANATORY NOTE On August 5, 2024, MediWound Ltd. (the "Company") issued a press release entitled "MediWound announces positive results from the U.S. NexoBrid Expanded Access Protocol (NEXT)". A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") as Exhibit 99.1. The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of senior management of the Company), is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: August 5, 2024 MEDIWOUND LTD. By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer EXHIBIT INDEX The following exhibit is filed as part of this Form 6-K: Exhibit Description 99.1 Press release dated August 5, 2024 entitled "MediWound announces positive results from the U.S. NexoBrid Expanded Access Protocol (NEXT)".

View Full Filing

View this 6-K filing on SEC EDGAR